VaxEquity was founded in 2020 by Imperial College London’s Professor Robin Shattock, and specialist life sciences investor Morningside, and is led by a world class team who are RNA pioneers. The Company is based in Cambridge, UK, and is collaborating with AstraZeneca to progress its platform across multiple disease areas.